Acepodia Past Earnings Performance
Past criteria checks 0/6
Acepodia's earnings have been declining at an average annual rate of -18.2%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 120.1% per year.
Key information
-18.2%
Earnings growth rate
9.4%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 120.1% |
| Return on equity | -12.7% |
| Net Margin | -4,925.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Acepodia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 17 | -817 | 142 | 311 |
| 31 Dec 22 | 0 | -1,414 | 176 | 342 |
| 31 Dec 21 | 0 | -879 | 174 | 303 |
Quality Earnings: 6976 is currently unprofitable.
Growing Profit Margin: 6976 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6976's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6976's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6976 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).
Return on Equity
High ROE: 6976 has a negative Return on Equity (-12.7%), as it is currently unprofitable.